HNN3.0
Register
Register
Register

Project cooperationUpdated on 17 December 2025

Rapid immune response novel platform, animal free

Lecturer in Glycosciences at University of Galway

Galway, Ireland

About

We have developed a NAM to profile immune response by multiplexed measuring of (serum) antibody response to antigens, and antibody effector function. Can measure IC50s and Kd (multiplexed). Can incorporate genetic variability in terms of immune receptors. This NAM can be used to advance research and regulatory testing, and categorise clinical response and for prognostics. Can be used with small molecules to model immune response. Measure and predict effector function of mAbs therapeutics, and vaccine responses.

Interested in participating in a project as a partner.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Type

  • Partner seeks Consortium/Coordinator

Organisation

University of Galway

University

Galway, Ireland

Similar opportunities

  • Project cooperation

    Rapid immune response novel platform, diagnostics prognostics

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Michelle Kilcoyne

    Lecturer in Glycosciences at University of Galway

    Galway, Ireland

  • Project cooperation

    AI-Driven Microfluidic 3D In Vitro Platform for Multi-Tissue Crosstalk in Drug Testing

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    MARCO BERZANO

    Research Manager and Advisor - Head of Medical Area at Università Politecnica delle Marche

    Ancona, Italy

  • Project cooperation

    B-cell mediated immune responses in health and disease.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Lesly Calderon

    Principal Investigator at Helmholtz Munich and TUM

    Munich, Germany